Assessment of geographic access to monoclonal antibodies in the United States

Benjamin Rader; Christopher M Whaley; Wesley S Rogers; Professor John S Brownstein; Jonathan Cantor

doi:10.1093/jtm/taac018

Assessment of geographic access to monoclonal antibodies in the United States

J Travel Med. 2022 May 31;29(3):taac018. doi: 10.1093/jtm/taac018.

Authors

Benjamin Rader^{1

2}, Christopher M Whaley³, Wesley S Rogers⁴, Professor John S Brownstein^{1

5}, Jonathan Cantor³

Affiliations

¹ Computational Epidemiology Lab, Boston Children's Hospital, Boston, MA, USA.
² Department of Epidemiology, Boston University School of Public Health, Boston, MA, USA.
³ RAND Corporation, Santa Monica, CA, USA.
⁴ NewYork- Presbyterian Hospital - Weill Cornell Medical Center, New York, NY, USA.
⁵ Harvard Medical School, Havard University, Boston, MA, USA.

Abstract

Using spatial modeling techniques, we highlight disparities in access to monoclonal antibodies (mAbs) used to treat COVID-19 patients. Fifteen million individuals in the United States must travel over 30 min to access mAbs. Areas with lower COVID-19 vaccination rates have worse access to essential COVID-19 therapeutics.

Keywords: COVID-19 treatment disparities; SARS-CoV-2 treatment; access to care; access to covid-19 care; access to treatment; antibody treatment; covid-19 treatment; monoclonal antibodies; monoclonal antibody.

Publication types

Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't

MeSH terms

Antibodies, Monoclonal* / therapeutic use
Geography
Health Services Accessibility*
Humans
United States

Substances

Antibodies, Monoclonal

Abstract

Publication types

MeSH terms

Substances

Grants and funding